Boston Scientific Corporation $BSX Shares Purchased by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC increased its holdings in Boston Scientific by 21.0%, acquiring a total of 216,910 shares valued at approximately $23.3 million.
• Several analysts have provided mixed ratings on Boston Scientific, with two analysts rating it as a Strong Buy while the average target price currently stands at $120.71.
• Insider selling activities have been reported, including a sale by Director Edward J. Ludwig of 4,000 shares and EVP Joseph Michael Fitzgerald selling 50,000 shares, reflecting a significant decrease in their ownership stakes.

Vanguard Personalized Indexing Management LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 21.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 216,910 shares of the medical equipment provider's stock after acquiring an additional 37,578 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Boston Scientific were worth $23,299,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BSX. Brighton Jones LLC lifted its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares during the last quarter. Wealthcare Advisory Partners LLC lifted its stake in Boston Scientific by 25.8% during the first quarter. Wealthcare Advisory Partners LLC now owns 3,675 shares of the medical equipment provider's stock worth $371,000 after purchasing an additional 754 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock valued at $2,578,000 after buying an additional 3,745 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in shares of Boston Scientific by 4.5% in the 1st quarter. Integrated Advisors Network LLC now owns 6,836 shares of the medical equipment provider's stock valued at $690,000 after buying an additional 296 shares during the period. Finally, West Branch Capital LLC raised its holdings in shares of Boston Scientific by 12,583.3% in the 1st quarter. West Branch Capital LLC now owns 761 shares of the medical equipment provider's stock valued at $77,000 after buying an additional 755 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BSX. Erste Group Bank downgraded Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Canaccord Genuity Group boosted their price objective on Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a report on Wednesday, October 1st. Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $120.71.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 in the last three months. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 1.9%

Shares of NYSE BSX opened at $95.41 on Friday. The stock has a market cap of $141.38 billion, a P/E ratio of 56.79, a PEG ratio of 2.30 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The business's fifty day simple moving average is $101.98 and its 200-day simple moving average is $101.86.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the firm earned $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.